EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer by Yongbin Zheng, Dan Song, Ming Guo, Chenhong Wang, Mingzhen Ma, Gongcai Tao, Licui Liu, Xiaobo He, Fengyu Cao, Dan Luo, Qingchuan Zhao, Zhongyuan Xia, Yanxin An

Subjects: Get full text

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer by Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff

Subjects: Get full text

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment by Khadijeh Falahzadeh, Fariba Esmaeili, Leila Nematollahi, Elham Bayat, Mehdi Khoobi, Mohammadali Mazloomi, Masumeh Jalalvand, Reza Faridi Majidi, Babak Negahdari

Subjects: “…cetuximab…”
Get full text

Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study by Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann

Subjects: Get full text

Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain by Ruth Alvarez Cabellos, Jon Cacicedo, Susana Redondo Capafons, Heidi De los Santos Real, Miriam Brines Julian, Dario Rubio-Rodriguez, Carlos Rubio-Terres

Subjects: “…cetuximab…”

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma by Wen-Chen Tang, Pei-Wei Huang, Chien-Yu Lin, Chia-Hsun Hsieh, Cheng-Lung Hsu, Shiang-Fu Huang, Chun-Ta Liao, Chih-Hua Yeh, Nai-Ming Cheng, Hung-Ming Wang*

Subjects: “…cetuximab…”
Get full text

STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB by O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko

Subjects: Get full text

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database by Shuai Zhao, Yan Wang, Xiaoli Deng, Xi Chen, Zhaoyi Lu

Subjects: “…Cetuximab…”
Get full text